Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed250%
recruiting125%
terminated125%

Recent Activity

1 active trials
Showing 4 of 4
terminatedphase_1

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

NCT05497336
recruitingphase_1

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

NCT05504278
completedphase_1

A Study of IBI351 in Healthy Subjects

NCT05699993
completedphase_1

A Study of IBI351 in Healthy Subjects

NCT05688124

Clinical Trials (4)

Showing 4 of 4 trials
NCT05497336Phase 1

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Terminated
NCT05504278Phase 1

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Recruiting
NCT05699993Phase 1

A Study of IBI351 in Healthy Subjects

Completed
NCT05688124Phase 1

A Study of IBI351 in Healthy Subjects

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4